Bernard Munos

5.3k total citations · 2 hit papers
12 papers, 3.5k citations indexed

About

Bernard Munos is a scholar working on Economics and Econometrics, Public Health, Environmental and Occupational Health and Immunology. According to data from OpenAlex, Bernard Munos has authored 12 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Economics and Econometrics, 8 papers in Public Health, Environmental and Occupational Health and 3 papers in Immunology. Recurrent topics in Bernard Munos's work include Pharmaceutical Economics and Policy (10 papers), Biotechnology and Related Fields (7 papers) and Biosimilars and Bioanalytical Methods (3 papers). Bernard Munos is often cited by papers focused on Pharmaceutical Economics and Policy (10 papers), Biotechnology and Related Fields (7 papers) and Biosimilars and Bioanalytical Methods (3 papers). Bernard Munos collaborates with scholars based in United States, Switzerland and India. Bernard Munos's co-authors include Aaron L. Schacht, Daniel S. Mytelka, Christopher T. Dunwiddie, Stacy Lindborg, Steven M. Paul, William W. Chin, Leonard Sacks, Brian M. Bot, Pei Wang and Michelle Crouthamel and has published in prestigious journals such as Science, Nature Reviews Drug Discovery and Annals of the New York Academy of Sciences.

In The Last Decade

Bernard Munos

12 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

How to improve R&D productivity: the pharmaceutical industry's grand challenge

2010 2.3k citations Steven M. Paul, Daniel S. Mytelka et al. Nature Reviews Drug Discovery profile →
Lessons from 60 years of pharmaceutical innovation

2009 795 citations Bernard Munos Nature Reviews Drug Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bernard Munos United States	10	1.2k	1.0k	800	497	444	12	3.5k
Stacy Lindborg United States	18	1.0k 0.9×	830 0.8×	544 0.7×	277 0.6×	340 0.8×	25	4.2k
Daniel S. Mytelka United States	9	1.0k 0.8×	820 0.8×	423 0.5×	258 0.5×	329 0.7×	18	2.6k
Aaron L. Schacht United States	7	987 0.8×	824 0.8×	407 0.5×	246 0.5×	326 0.7×	8	2.5k
Christopher T. Dunwiddie United States	21	1.2k 1.0×	847 0.8×	405 0.5×	249 0.5×	335 0.8×	38	3.5k
Ronald W. Hansen United States	8	1.3k 1.0×	1.1k 1.0×	2.2k 2.8×	721 1.5×	452 1.0×	9	5.2k
John Arrowsmith United Kingdom	13	1.3k 1.1×	835 0.8×	310 0.4×	177 0.4×	383 0.9×	19	3.3k
Hu Y Macao	34	1.6k 1.3×	249 0.2×	261 0.3×	138 0.3×	235 0.5×	250	4.3k
Asher Mullard Canada	53	4.9k 3.9×	870 0.8×	433 0.5×	338 0.7×	656 1.5×	604	9.9k
Joseph A. DiMasi United States	28	1.8k 1.5×	1.5k 1.4×	4.0k 4.9×	1.3k 2.6×	668 1.5×	70	8.6k
Jürgen Drews Austria	22	2.0k 1.6×	590 0.6×	140 0.2×	211 0.4×	194 0.4×	64	3.6k

Countries citing papers authored by Bernard Munos

Since Specialization

Citations

This map shows the geographic impact of Bernard Munos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bernard Munos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bernard Munos more than expected).

Fields of papers citing papers by Bernard Munos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bernard Munos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bernard Munos. The network helps show where Bernard Munos may publish in the future.

Co-authorship network of co-authors of Bernard Munos

This figure shows the co-authorship network connecting the top 25 collaborators of Bernard Munos. A scholar is included among the top collaborators of Bernard Munos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bernard Munos. Bernard Munos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

1.

Sim, Ida, Michael Stebbins, Barbara E. Bierer, et al.. (2020). Time for NIH to lead on data sharing. Science. 367(6484). 1308–1309. 37 indexed citations

2.

Munos, Bernard, et al.. (2016). Disruptive Innovation and Transformation of the Drug Discovery and Development Enterprise. NAM Perspectives. 6(7). 5 indexed citations

3.

Munos, Bernard, Brian M. Bot, Michelle Crouthamel, et al.. (2016). Mobile health: the power of wearables, sensors, and apps to transform clinical trials. Annals of the New York Academy of Sciences. 1375(1). 3–18. 69 indexed citations

4.

Munos, Bernard. (2015). How to handle an industry in disruption: Intervene or laissez-faire?. Science Translational Medicine. 7(286). 286ps12–286ps12. 2 indexed citations

5.

Munos, Bernard. (2013). A Forensic Analysis of Drug Targets From 2000 Through 2012. Clinical Pharmacology & Therapeutics. 94(3). 407–411. 13 indexed citations

6.

So, Anthony D., Samir K. Brahmachari, I. Chopra, et al.. (2011). Towards new business models for R&D for novel antibiotics. Drug Resistance Updates. 14(2). 88–94. 49 indexed citations

7.

Munos, Bernard & William W. Chin. (2011). How to Revive Breakthrough Innovation in the Pharmaceutical Industry. Science Translational Medicine. 3(89). 89cm16–89cm16. 68 indexed citations

8.

Munos, Bernard. (2010). Can Open-Source Drug R&D Repower Pharmaceutical Innovation?. Clinical Pharmacology & Therapeutics. 87(5). 534–536. 42 indexed citations

9.

Paul, Steven M., Daniel S. Mytelka, Christopher T. Dunwiddie, et al.. (2010). How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nature Reviews Drug Discovery. 9(3). 203–214. 2338 indexed citations breakdown →

10.

Munos, Bernard. (2009). Lessons from 60 years of pharmaceutical innovation. Nature Reviews Drug Discovery. 8(12). 959–968. 795 indexed citations breakdown →

11.

Munos, Bernard & William W. Chin. (2009). A Call for Sharing: Adapting Pharmaceutical Research to New Realities. Science Translational Medicine. 1(9). 9cm8–9cm8. 29 indexed citations

12.

Munos, Bernard. (2006). Can open-source R&D reinvigorate drug research?. Nature Reviews Drug Discovery. 5(9). 723–729. 69 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact